Read the November issue

Including articles on gene therapies, targeting G-protein-coupled receptors with antibodies and therapeutic strategies for idiopathic pulmonary fibrosis. 

Latest Reviews

  • Review |

    Lysosomal storage disorders (LSDs) are rare, inherited metabolic disorders that result from defects in lysosomal function, for which treatment options are limited. Here, Platt provides an overview of LSDs, approved and potential therapeutic approaches and agents currently in development. The challenges associated with LSD diagnosis, drug development and treatment are discussed.

    • Frances M. Platt
  • Review |

    Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines. Jakinibs — small-molecule inhibitors of JAKs — have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies. This Review discusses the biology, development and efficacy of jakinibs in the treatment of immune and inflammatory diseases.

    • Daniella M. Schwartz
    • , Yuka Kanno
    • , Alejandro Villarino
    • , Michael Ward
    • , Massimo Gadina
    •  & John J. O'Shea
  • Analysis |

    G protein-coupled receptors (GPCRs) are the most intensively studied class of drug targets. This article presents a pioneering analysis of all GPCR-targeted drugs and agents that are currently in clinical trials, and discusses the trends across molecule types, drug targets and therapeutic indications.

    • Alexander S. Hauser
    • , Misty M. Attwood
    • , Mathias Rask-Andersen
    • , Helgi B. Schiöth
    •  & David E. Gloriam
  • Analysis |

    Shih and colleagues analyse comprehensive industry-wide data on drug development projects pursued during the past 20 years, classified according to the mechanism and indication for each project. Their findings indicate several points and trends that may be useful in understanding and improving the productivity of the pharmaceutical industry, including areas with substantial success or failure and the relative extent of novelty in completed and ongoing projects.

    • Hsin-Pei Shih
    • , Xiaodan Zhang
    •  & Alex M. Aronov
  • Review |

    WD40 repeat (WDR) domain-containing proteins are involved in numerous protein complexes that have been linked to disease. Schapira and colleagues describe recent advances in targeting WDR domains with small molecules to potently inhibit protein–protein interactions, and discuss the potential for the diversity and druggability of WDR domains to open up new pathways for therapeutic intervention.

    • Matthieu Schapira
    • , Mike Tyers
    • , Maricel Torrent
    •  & Cheryl H. Arrowsmith
  • Review |

    Aggregates of the microtubule-associated protein tau are a defining feature of several neurodegenerative disorders, including Alzheimer disease (AD). Given the recent failures of several amyloid-β-targeted therapies for AD, interest is growing in tau as an alternative target, and this Review describes preclinical and clinical studies of tau-based approaches in the light of recent advances in the understanding of the physiological and pathological roles of tau.

    • Chuanzhou Li
    •  & Jürgen Götz

News & Comment